Chen Ming, Jin Ying, Bi Yalan, Li Yan, Shan Ying, Pan Lingya
1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Cancer. 2015 Feb 27;6(5):412-9. doi: 10.7150/jca.11242. eCollection 2015.
To assess the effects of lymphovascular space invasion (LVSI) on cancer recurrence and survival in patients with primary epithelial ovarian cancer.
A retrospective study was conducted of patients with stage I-IV primary epithelial ovarian cancer who underwent cytoreductive surgery. LVSI is defined as the presence of tumor cells within an endothelium-lined space, and the patients' pathologic slides were reevaluated by gynecological pathologists. Survival analysis was performed to compare risk factors.
A total of 492 patients were included in the analysis. The incidence of LVSI was 58.5% in our cohort (288 cases), and it was significantly associated with advanced stage, high-grade serous histology, high grade, and lymph node metastasis (P<0.001). Kaplan-Meier analysis demonstrated that LVSI was only correlated with decreased PFS (5-year rate, 39% vs. 66%, P<0.001) and OS (5-year rate, 44% vs. 78%, P<0.001) in patients at early stage but not at advanced stage (5-year rate, PFS: 14% vs. 11%, P<0.001; OS: 29% vs. 29%, P=0.141). Multivariate analysis showed that LVSI remained a significant variable with PFS and OS in early-stage ovarian cancer (PFS: HR 2.29, 95% CI 1.45-3.57; OS: HR 2.20, 95% CI 1.59-3.44, both P<0.001).
LVSI is an independent predictor of progression and survival in patients with primary epithelial ovarian cancer at early stage but not at advanced stage.
评估淋巴管侵犯(LVSI)对原发性上皮性卵巢癌患者癌症复发和生存的影响。
对接受肿瘤细胞减灭术的Ⅰ-Ⅳ期原发性上皮性卵巢癌患者进行回顾性研究。LVSI定义为在内皮细胞衬里的腔内存在肿瘤细胞,患者的病理切片由妇科病理学家重新评估。进行生存分析以比较危险因素。
共有492例患者纳入分析。我们队列中LVSI的发生率为58.5%(288例),并且它与晚期、高级别浆液性组织学、高级别和淋巴结转移显著相关(P<0.001)。Kaplan-Meier分析表明,LVSI仅与早期患者的无进展生存期(5年率,39%对66%,P<0.001)和总生存期(5年率,44%对78%,P<0.001)降低相关,而与晚期患者无关(5年率,无进展生存期:14%对11%,P<0.001;总生存期:29%对29%,P=0.141)。多因素分析显示,在早期卵巢癌中,LVSI仍然是无进展生存期和总生存期的显著变量(无进展生存期:风险比2.29,95%置信区间1.45-3.57;总生存期:风险比2.20,95%置信区间1.59-3.44,均P<0.001)。
LVSI是原发性上皮性卵巢癌早期而非晚期患者病情进展和生存的独立预测因素。